<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01097382</url>
  </required_header>
  <id_info>
    <org_study_id>ZOLPI_L_04551</org_study_id>
    <secondary_id>U1111-1116-9105</secondary_id>
    <nct_id>NCT01097382</nct_id>
  </id_info>
  <brief_title>Sleep Satisfaction and Psychomotor Performance of Adults</brief_title>
  <acronym>MORFEO CR</acronym>
  <official_title>National, Multicenter, Open Label, Phase IV, Before-after Design Study, in Adult Patients With Primary Insomnia to Evaluate Sleep Satisfaction and Psychomotor Performance After 1 Month of Treatment With Zolpidem CR (AmbienÂ®CR) in 6 Sites in Argentina</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary Objective:

      To assess sleep satisfaction before and after Zolpidem CR (Ambien CR) administration

      Secondary Objective:

      To assess Psychomotor Performance before and after Zolpidem CR (Ambien CR) administration
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sleep satisfaction score (LSEQ = Leeds sleep evaluation questionnaire)</measure>
    <time_frame>at Baseline, at V2 (26 +/- 2 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psychomotor Performance (DSST / Digit Symbol Substitution Test and ESS / Epworth Sleepiness Scale)</measure>
    <time_frame>at Baseline, at V2 (26 +/- 2 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Sleep Disorders</condition>
  <arm_group>
    <arm_group_label>AMBIEN CR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMBIEN CR 12.5 mg once daily immediately before bedtime or in elderly/hepatically impaired patients: 6.25 mg once daily immediately before bedtime</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZOLPIDEM</intervention_name>
    <description>Pharmaceutical form: tablet Route of administration: oral Dose regimen: once daily</description>
    <arm_group_label>AMBIEN CR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients consulting Psychiatrists (private or hospital) -whatever the reason for
             consulting- who present with chronic primary insomnia from the DSM IV (Diagnostic and
             Statistical Manual - Revision 4).

          -  Accepting to participate in the study and signing informed consent

        Exclusion criteria:

          -  Pregnancy or breastfeeding.

          -  Current severe neuropsychiatric disorder (i.e. psychosis, obsessive compulsive
             disorder, major depression, dementia of Alzheimer or vascular type) according to DSM
             IV criteria.

          -  History of substance abuse or dependence (including alcohol) within the past year.

          -  Hypersensitivity to zolpidem or its excipients.

          -  Severe hepatic insufficiency

          -  Severe and/or acute respiratory insufficiency

          -  Myasthenia gravis.

          -  OTC (Over The Counter) sleep remedies or prescription sleep medications within 2 weeks
             or 5 half-life before screening.

          -  Severe medical illness.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 10</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1</name>
      <address>
        <city>C.a.b.a.</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4</name>
      <address>
        <city>C.a.b.a.</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6</name>
      <address>
        <city>C.a.b.a.</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2</name>
      <address>
        <city>Capital Federal</city>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3</name>
      <address>
        <city>La Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2010</study_first_submitted>
  <study_first_submitted_qc>March 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2010</study_first_posted>
  <last_update_submitted>July 16, 2012</last_update_submitted>
  <last_update_submitted_qc>July 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolpidem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

